Abstract | A subset of patients with IBS have visceral hypersensitivity and/or somatic hypersensitivity. Visceral hypersensitivity might have use as a clinical marker of IBS and could account for symptoms of urgency for bowel movements, bloating and abdominal pain. The mechanisms that lead to chronic visceral hypersensitivity in patients who have IBS are unclear. However, several working models may be considered, including: nociceptive input from the colon that leads to hypersensitivity; increased intestinal permeability that induces a visceral nociceptive drive; and alterations in the expression of microRNAs in gastrointestinal tissue that might be delivered via blood microvesicles to other target organs, such as the peripheral and/or central nervous system. As such, the chronic visceral hypersensitivity that is present in a subset of patients with IBS might be maintained by both peripheral and central phenomena. The theories underlying the development of chronic visceral hypersensitivity in patients with IBS are supported by findings from new animal models in which hypersensitivity follows transient inflammation of the colon. The presence of somatic hypersensitivity and an alteration in the neuroendocrine system in some patients who have IBS suggests that multisystemic factors are involved in the overall disorder. Thus, IBS is similar to other chronic pain disorders, such as fibromyalgia, chronic regional pain disorder and temporomandibular joint disorder, as chronic nociceptive mechanisms are activated in all of these disorders.
Introduction
IBS is a gastrointestinal disorder that affects up to 20% of the population of the USA and is associated with an alteration in bowel habits (such as diarrhea and constipa tion). Patients with IBS have a considerably decreased quality of life and utilize large amounts of healthcare resources. A subset of patients who have IBS, varying from 30% to 40%, are reported to exhibit enhanced sensi tivity to colonic distension, which is noticeable through their reduced threshold for pain, increased intensity of sensations and/or exaggerated viscerosomatic refer ral in response to colonic distension. [1] [2] [3] [4] Thus, visceral hypersensitivity is a clinical marker in a subset of patients who have IBS and could account for the symptoms of urgency for bowel movements, bloating and abdominal pain experienced by these patients. However, the correla tion between hypersensitivity and clinical symptoms and outcomes is still not clearly defined. 5 The findings of a study published in 2006 revealed that habituation of vis ceral hypersensitivity by repeated exposure to noxious stimuli occurred without any change in the severity of IBS symptoms. 6 The cause of visceral hypersensitivity is unknown; however, a number of mechanisms have been postulated, such as inflammation or sensitization after an injury. 1 Several studies have shown that some patients develop IBS symptoms following enteric infection of the gut. [7] [8] [9] Although the exact mechanism or mechanisms under lying postinfectious IBS are not clearly understood, increased intestinal permeability has been reported in these patients. 11 Interestingly, a study published in 2010 demonstrated that a subset of patients with IBS have increased intestinal permeability that is associated with decreased levels of glutamine synthetase in the gut. 11 In this Review, we discuss the mechanisms associated with somatic and visceral hypersensitivity in patients who have IBS. We review the experimental evidence for both visceral and secondary somatic hyper sensitivity in patients with IBS and then discuss several possible underlying mechanisms-impulse input from the colon in the induction and maintenance of hyper sensitivity, increased intestinal permeability, and alterations in microRNA (miRNA) expression in gastrointestinal tissues that might be delivered via blood microvesicles to other target organs. These unifying mechanisms suggest that there is a synergistic interaction between peripheral and central nervous system mechanisms that may have an important role in the pathophysiology of the pain and hypersensitivity often seen in patients who have IBS.
Neurobiology of visceral afferents
The responses of visceral afferents are elicited by chemi cal stimuli, local luminal stimuli and by mechanical stimuli (such as gastrointestinal distension). Silent nociceptors also exist that are mechanically insensi tive until tissue injury occurs, after which they develop spontaneous activity and mechanosensitivity. 12 For example, acute instillation of bile salts into the colon considerably increases the activity of mechanosensitive colonic afferents in response to colonic distension. 13, 14 When silent nociceptors are activated, they could then contribute to chronic visceral hypersensitivity via both peripheral and central nervous system mechanisms. A superior understanding of the mechanisms that lead to chronically altered sensations from the viscera has come from an improved understanding of primary visceral afferent physiology. Disorders in which patients experi ence altered sensations include ureteric colic, functional bowel disorders (such as IBS) and interstitial cystitis. 1, 13 As mentioned above, although after acute injury vis ceral afferents can develop a state of acute mechano sensitization, mounting evidence indicates that chronic hyperalgesia is a consequence of persistent tissue injury. Animal models of visceral hypersensitivity exist in which irritation of the colon causes chronic visceral hyper sensitivity and central sensitization that is associated with allodynia and hyperalgesia. [15] [16] [17] Similarly, IBS symp toms develop in ~20-25% of patients after Salmonella infection of the gut. 18, 19 Although many acute symptoms typically disappear within several weeks of the initiation of symptoms, bloat ing, diarrhea and abdominal symptoms do not. Transient inflammation of the colon might sensitize the gut, and the sensitization can persist long after resolution of the inflamma tion. This pattern is similar to that seen in the animal models of functional gastrointestinal dis orders noted above. [15] [16] [17] However, our understanding of colonic and/or peripheral afferents that become sensitized and contribute to chronic visceral hyper sensitivity is still poor. Hyperalgesia involves elements from the periph eral and central nervous systems and might be entirely maintained by either central or peripheral mechanisms.
The neuroendocrine system in IBS
Some of the early investigations of somatic hyper sensitivity in patients with IBS suggested that the hypersensitivity was limited to the gut. [20] [21] [22] Sensitivity in other areas of the body was either reduced or unaffected in patients with IBS compared with healthy control partici pants matched for age and sex. [20] [21] [22] The findings of these early studies might be explained by the stimuli A study published in 2010 investigated the perception of somatic pain in patients who have IBS. 4 In this study, several experimental procedures were used to induce somatic pain and look at different perceptual qualities and stimulus intensities across body sites that provided input to the spine at differing levels. Some patients with IBS had greater sensitivity to somatic (for example, thermal, cold pressor or ischemic) stimuli than control individuals did. After thermal and cold pressor stimuli this difference was noticeable for the foot, but not the hand, which suggests that thermal hypersensitivity is somatotopically organized in patients who have IBS, with dermatomes on the lower body showing greater hyper sensitivity than dermatomes on the upper body. Thus, a subset of patients with IBS have greater sensitivity to somatic stimuli than control individuals. Interestingly, there were no differences in somatic sensitivity between patients who have IBS and control individuals when mechanical stimuli were used.
These results support the findings from a study that tested the pain perception of patients with IBS who either did or did not have fibromyalgia. 25 During an ascend ing series of pressure (mechanical) stimuli, patients with IBS had similar pain thresholds to control individuals. 25 A possible reason for this finding in patients who have IBS that differs from the reasons underlying the response to thermal, cold pressor and ischemic stimuli, might be related to the differences in stimulus modalities. Mechanical stimuli activate nonnociceptive mechano receptors at higher levels in the cerebral cortex, which could be inhibited by chronic visceral nociceptive input in patients who have IBS. 24 Thus, total nociceptive input with mechanical stimuli might be reduced in patients who have IBS compared with nociceptive input from thermal stimuli.
The cold pressor test has also been used to test somatic hypersensitivity in patients who have IBS. 21, 22 These patients have shown a notably higher perception of pain in response to the cold pressor applied to the foot com pared with when it is applied to the hand. 4 Interestingly, these findings are different from one study that showed hypersensitivity in patients who have IBS using cold pressor testing applied to the hand and to two studies that did not find any hypersensitivity in patients who have IBS. 3, 21, 22 These differences might be explained by the fact that there is a subset of patients who have IBS whose pain threshold for cold water is similar to control individuals, and a small group of patients with IBS who have a much lower pain threshold for the cold pressor test than either control individuals or other patients with IBS. Further analysis of subsets of sensitive patients who have IBS might, therefore, prove interesting and could enable the identification of the frequency distribution of hypersensitivity in patients with IBS.
The modified submaximal effort tourniquet proce dure (an ischemic test) has been used to evaluate somatic hypersensitivity in patients who have IBS. 26 The ischemic test activates a large number of C fibers in the muscle and produces a diffuse, deep pain. This activation is different from other nociceptive stimuli that primarily involve Aδ fibers, as the cutaneous stimuli were of shorter duration than in the ischemic test. 26, 27 Compared with the thermal and cold pressor stimuli in a recent study, 4 the ischemic test revealed a larger subset of patients who have IBS with hypersensitivity. Other studies have reported isch emic hypersensitivity using the modified submaximal effort tourniquet procedure in patients with temporo mandibular disorders, fibromyalgia or inter stitial cystitis. [27] [28] [29] All of these disorders have considerable comorbidity and overlap of symptoms with IBS.
As there is a robust subset of patients who have IBS with hypersensitivity during the ischemic test, changes in the levels of cortisol and adrenocorticotropic hormone (ACTH) were measured in the study by Zhou et al. 4 Following the ischemic test, patients with IBS, but not control individuals, had a considerable increase in levels of both cortisol and ACTH. The changes in the levels of cortisol and/or ACTH following the thermal or cold pressor stimuli were not statistically significant (Figure 1) . 4 The increase in the levels of cortisol and ACTH following an ischemic test suggests that patients who have IBS might experience this stimulus as more stressful than patients who do not have IBS. 30 These results are similar to those of another study that demon strated differences in the adrenocortical response to stress in patients with IBS compared with the response in control individuals. 31 Overall, the findings of the above studies are consis tent with the idea that a subset of patients who have IBS display somatic hypersensitivity. 4 Given that the somatic hypersensitivity in patients with IBS is somatotopically organized, it is tempting to conclude that afferent noci ceptive input from the gastrointestinal tract can sensi tize spinal neurons that overlap somatotopically with the gastrointestinal tract. As subsets of patients who have IBS and hypersensitivity to cold pressor, ischemic and thermal stimuli exhibited only a small amount of overlap, several mechanisms could be involved. Overlap of cold pressor, ischemic and thermal hypersensitivity was only found in a small subset of patients who have IBS. In these patients, the largest overlap in somatic hypersensitivity was observed between the thermal and cold pressor tests (Figure 1 ). Differing modalities and mechanisms of hypersensitivity might, therefore, underlie this unique subset of patients who have IBS with somatic hypersensitivity.
Gastrointestinal afferent input
One plausible mechanism underlying secondary somatic hypersensitivity in patients who have IBS is a chronic afferent barrage from the colon to the spinal cord. This mechanism has been studied in both humans and in animal models of visceral hypersensitivity, as discussed above. Several animal models of neuropathic pain have been used to demonstrate that persistent afferent input to the spinal cord from peripheral sources sustains altered central processing and leads to spontaneous motor abnormalities, hyperalgesia, pain and allodynia. [15] [16] [17] These models are based on the finding that blockade of nociceptive input from specific somatic foci by peripheral anesthetics abrogates pain and allodynia induced by cold or mechanic stimuli within widespread regions of the body in patients with complex regional pain syndrome. 32 As widespread zones of hypersensitivity are present in patients with fibromyalgia, neuropathic pain and IBS, these regions of hypersensitivity could be maintained, at least in part, by tonic impulses from nociceptive colonic afferent neurons.
Two studies have evaluated the effects of lidocaine (a local anesthetic) on colonic distension. One study demon strated that administration of rectal lidocaine did not alter sensation to rectal distension (either phasic or ramp distension) in patients with IBS. 33 By contrast, another study showed that rectal lidocaine inhibited sensa tion to slow ramp but not rapid phasic distension in healthy individuals; patients with IBS were not tested in this study. 34 The role of tonic impulse input from the gut of patients who have IBS has also been tested by administering lido caine jelly to the colon in a doubleblind crossover trial. 35 Interestingly, intracolonic lidocaine diminished hyper sensitivity to both nociceptive colonic distension and thermal stimuli applied to the foot. The same results have been demonstrated in an animal model of IBS in which intracolonic lidocaine normalized both colonic and thermal hypersensitivity in hypersensitive rats. 36 In both of these studies, there were no detectable levels of lido caine in the blood for up to 50 min following administra tion, which suggests that the findings were not caused by lidocaine being systemically absorbed. These results are in accordance with a role for peripheral impulse activ ity in conditions of neuropathic pain. Such conditions are present in situations in which tonic impulses from a peripheral source dynamically sustain the primary hypersensitivity caused by input from the gut as well as the secondary somatic hypersensitivity that is distant (for example, in an extremity) from the peripheral source of impulse input (in this case, the gut). 32 Currently, there are few ways to test spinal cord mech anisms of hypersensitivity in patients who have IBS. One study used electromyographic recordings of somatic nociceptive flexion reflexes (RIII) after painful electric shocks in the foot area to evaluate the effect of colonic distension. 37 Distension of the colon induced inhibi tion of this nociceptive reflex in 10 healthy volunteers; it accentuated this reflex in 14 patients who had IBS. These results strongly suggest that hyperexcitability of spinal nociceptive processing might occur in patients with IBS. Another study of patients who have IBS showed that a subset of these patients have marked temporal summa tion of second pain (also known as windup) in response to a series of noxious heat pulses with a low peak inten sity (47 °C). 38 The presence of windup in this subset of patients who have IBS is interesting and was blocked by the NMDA receptor antagonist, dextromethorphan. The presence of windup is important in the induction and/or maintenance of chronic disorders that involve allodynia and hyperalgesia. 23, 24 So, the somatic hypersensitivity that is present in a subset of patients with IBS could result from temporal summation via excessive activation of central NMDA receptors. Heightened central sensitiza tion could explain the chronic pain present in the distinct subsets of patients who have IBS described above. 4 The strongest evidence for spinal cord mechanisms of hypersensitivity in patients with IBS comes from several animal studies. One model shows that ~24% of rats treated with intracolonic trinitrobenzene sulfonic acid (TNBS) develop hypersensitivity to both noci ceptive colonic distension and thermal stimuli following reso lution of TNBSinduced colitis. 15 Similar to findings in patients with IBS, the somatic hypersensitivity was greater in the lumbosacral dermatomes compared with the cervicothoracic dermatomes. Another study, which used an animal model that was IBSlike, showed that expression of the subunits of the NMDA NR1 protein in hypersensitive animals was greater in the L4-S1 region (laminae I and II) of the spinal cord than in the T10-L1 region of the spinal cord. 23 In this animal model, the somatic hypersensitivity is organized somatotopically, with dermatomes in the lower body showing a greater hypersensitivity than those in the upper body. In another animal model, neonatal rats were injected with mustard oil, which induced delayed visceral and somatic hyper sensitivity, similar to the effects of treating animals with TNBS. 16 In the same study, dorsal horn neurons that received both colonic and somatic input had increased levels of evoked impulse activity from colonic disten sion and somatic stimuli as well as increased spontane ous activity. This finding provides further evidence that both visceral and somatic hypersensitivity in patients with IBS might be dynamically maintained by primary colonic afferent neurons and consequent sensitization of the dorsal horn neurons on which they synapse.
The role of the central nervous system in modulat ing visceral hypersensitivity has also gained increas ing importance over the past decade. Activation of the central nervous system in animal models of visceral hypersensitivity has been shown in response to increased levels of cFos in the central nervous system. 39 Levels of corticotropinreleasing factor, an important regulator of the stress response, are increased in several brain structures in rat models of functional bowel disorders. 40, 41 Thus, targeting central nervous system structures with cognitive behavioral therapy or other central therapies might lead to important treatment modalities for IBS, such as using amitriptyline. 42 
Increased intestinal permeability
The purposes of the gastrointestinal tract are to help nutrients to be absorbed and to act as a barrier to the absorption of toxic compounds, macromolecules and bacteria. 43, 44 Disruption of the gut barrier can cause local gastrointestinal dysfunction and systemic abnormali ties (for example, bacterial translocation and sepsis). Alterations in the mechanical barrier or the immune barrier contribute to an increased uptake into the sys temic circulation of pathogenic bacteria and inflamma tory luminal macromolecules. Increased intestinal barrier permeability seems to correlate with several clini cal condi tions, including food allergies, IBD, rheuma toid arthritis, allergic disorders, celiac disease and a few chronic dermatological conditions. 43 In the latest literature, there has been a focus on enhanced intestinal perme ability as a possible causative factor in IBS. 10 In patients with postinfectious IBS, it is hypothesized that ongoing subclinical inflammation with an increase in intestinal permeability, mast cells, proinflammatory cytokines, serotonincontaining enterochromatin cells and T lymphocytes could be involved. 45, 46 The intestinal mucosa of some patients with IBS contains an increased number of immunocytes (such as T lymphocytes and mast cells) and there is evidence of an increase in the release of cytokines, histamine, proteases and prosta glandins. 45 These mediators are known to signal to epi thelial, neu ronal and muscle cells, which leads to intestinal dysfunc tion. The activation of these inflammatory factors might lead to increased intestinal permeability, especially in a subset of patients with diarrhea predominant IBS.
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Hyperpermeability permits bacteria and antigens to translocate through the gut mucosa. Such translocation can activate symptoms seen in patients who have IBS, including abdominal pain, mucosal immune responses and the attendant chronic diarrhea. Interestingly, animal models have shown that increased intestinal perme ability induces hyper sensitivity. In one study, acute partial restraint stress considerably increased colonic perme ability in addition to abdominal muscle electromyo graphy in response to colonic distension. 47 Increased intestinal permeability has been evalu ated in a subset of patients with diarrheapredominant IBS. 48 Those who had intestinal hyperpermeability also had higher Functional Bowel Disorder Severity Index (FBDSI) scores than those without hyperpermeability. The increase in the FBDSI scores correlated positively with increases in visceral and thermal hypersensitivity. In the subset of patients who have IBS with diarrhea as the predominant symptom, intestinal hyper permeability could contribute to a chronic nociceptive drive from the gastrointestinal tract to the spinal cord, and lead to central sensitization. The study also showed a correla tion between the severity of IBS symptoms (as monitored by the FBDSI scale) and the presence of both visceral and somatic hypersensitivity. In addition, patients who have IBS with somatic and visceral hypersensitivity exhibit increased intestinal permeability. 48 The intestinal hyperpermeability could permit passage of inflammatory agents and bacteria through the gut wall, which would sensitize the myenteric plexus and overlapping common spinal segments. This spinal sensitization in patients with IBS could be created and/or maintained by tonic impulse input from the colon to the spinal cord. The FBDSI score in patients with IBS was positively correlated with both an increase in intestinal permeability and visceral and thermal hypersensitivity. Patients who have IBS, a high FBDSI score and increased intestinal permeability might, therefore, have central sensitization that would justify alternative treatment modalities aimed at the central nervous system.
The human gastrointestinal tract is the major site of glutamine utilization in the body. Glutamine is a major energy source for rapidly dividing intestinal mucosal cells of the digestive tract. Glutamine also helps to protect the lining of the gastrointestinal tract. Depletion of glutamine results in epithelial atrophy and a subsequent increase in intestinal permeability. Glutamine supplementation decreases bacterial translocation and intestinal perme ability after intestinal injury. 49 Glutamine supplementa tion also decreases intestinal permeability and improves gastrointestinal function in patients with Crohn's disease and in patients with advanced esophageal cancer who are undergoing radiochemotherapy. 50, 51 Glutamine synthetase catalyzes the conversion of ammonia and glutamate to glutamine. This enzyme has a major role in cell signaling, ammonia detoxification, interorgan nitrogen flux and acid-base homeostasis. Congenital glutamine deficiencies have been reported in children with glutamine synthetase mutations. 52 Because of the multiple functions and importance of glutamine synthetase in cellular metabolism, catalytic activities and synthesis are both highly regulated. Glutamine synthetase is also important for cell proliferation in the rat intestinal crypt cells. 53 Mucosal epithelial cells that line the gastrointestinal tract have a small free glu tamine pool and rely on glutamine synthetase to convert glutamate and ammonia to glutamine. Inhibition of glu tamine synthetase decreased proliferation of cultured rat intestinal cells. 53 Consequently, conditions in which decreased levels of intestinal glutamine synthetase are present might lead to low levels of available glutamine and increased intestinal permeability, as is seen in some patients with diarrheapredominant IBS.
Alterations in microRNA expression miRNAs were identified in 1993 as small (~21-23 nucleo tides long), endogenous, noncoding RNAs that have the capacity for gene regulation in larval development. 54, 55 Mature miRNAs are cleaved from 70-100 nucleotide hairpin premiRNA precursors. Singlestranded miRNAs bind through partial sequence homology to the 3' untranslated region of target messenger (m)RNAs and cause a block of translation or, less frequently, mRNA degradation. Over the past decade, miRNAs have emerged as regulators involved in biological processes, such as cellular development, differentiation, prolifera tion, apoptosis and metabolism. 56 Several studies have indicated that miRNAs can be used as a marker in patients with gastrointestinal diseases. In patients who have IBS, miRNA expression is altered in colonic tissue and these miRNAs regulate intestinal pathways, which results in epigenetic and genetic events. These changes could also lead to alterations in intestinal perme ability, serotonin signaling, or visceral/somatic hyper sensitivity. 11, 57, 58 Alterations in gastrointestinal functional processes, such as intestinal permeability, can be altered by the expression of specific miRNAs, such as miR29a. 11 Interestingly, miR29a has a complementary site in the 3' untranslated region of the gene that encodes glutamine synthetase, as predicted by a wellestablished database that predicts miRNA target genes. 59 Because of the complementary site in the GLUL gene, altered miR29a expression leads to decreased glutamine synthetase levels. Decreased levels of glutamine synthetase might lead to decreased intestinal levels of glutamine, which results in an increased intestinal perme ability. 11 This finding supports a role for miR29a in regulating intesti nal permeability in patients with diarrhea predominant IBS. This new discovery links the pathophysiology of IBS to a specific miRNA that modulates the integrity of the intestinal barrier.
Blood microvesicles are spherical membrane fragments that act as celltocell and celltoorgan communi cators and are shed from the surface of most cells. 60, 61 Most cells release microvesicles from their plasma membrane (microparticles) or from multivesicular endocytic compart ments (exosomes). Microvesicles directly target cells via receptormediated interactions or potentially by transferring various bioactive molecules, including membrane receptors, proteins, mRNAs, miRNAs and organelles. Shedding of membranederived microvesicles accompanies cell activation. 60, 61 Changes in the molecular signature of microvesicles could also be used to identify certain disease processes.
Unique blood microvesicles with increased expres sion of the miRNA miR29a have been identified in patients with diarrheapredominant IBS. 11 Alterations in miRNA expression found in circulating blood micro vesicles in patients who have IBS might be derived from colonic tissue. Alteration of miRNA expression probably occurs at the site of tissue injury (the colon) in patients who have IBS. These altered microvesicles might then travel to distant sites where they directly modulate downstream targets.
Conclusions
IBS is a common gastrointestinal disorder and a subset of patients with IBS have visceral and somatic hyper sensitivity. The mechanisms underlying this hyper sensitivity are unknown; however, there are several possible working models: impulse input from the colon in the induction and maintenance of hypersensitivity; increased intestinal permeability that induces and/or maintains a visceral nociceptive drive; and alterations in miRNA and microvesicles in target tissues. Other, as yet undiscovered, mechanisms may also be involved. How these potential mechanisms interact and produce a synergistic relationship between peripheral and central mechanisms in patients who have IBS requires further study. Thus, the mechanisms of hypersensitivity in IBS are still unclear but are probably induced by physiologic stimuli, such as transient inflammation of the gut or increased intestinal permeability. A subset of patients with IBS have persistent hypersensitivity in response to experimental pain stimuli. Future studies need to be done to determine the underlying neurobiology that is present in this subset of patients. These studies might then lead to the develop ment of more effective and tar geted therapies than those currently available for this group of hypersensitive patients.
